THE DEVIL IS IN THE DETAILS - A CHECKLIST FOR DEVELOPING SUCCESSFUL EU PHARMA AND MEDTECH FORECASTS
Forecasting the value of biopharmaceutical and Med Tech assets often begins with the US market due to its size and significance. However, successfully transitioning these forecasts to European markets or beginning with a Europe-first strategy requires careful consideration and expertise, often leading to redefinition of forecast structures and assumptions. Drawing on examples from our extensive forecasting experience, we outline a comprehensive checklist that highlights the critical differences between the US and European markets and forecasts.
KEY TAKEAWAYS:
- EXPLORE KEY MARKET DIFFERENCES: UNDERSTAND HOW VARIATIONS IN MARKET LANDSCAPES, PATIENT AND PRESCRIBER ATTITUDES AND BEHAVIORS, REGULATION, AND MARKET ACCESS AND PRICING ENVIRONMENTS INFLUENCE THE STRUCTURE AND ASSUMPTIONS UNDERLYING EU FORECASTS.
- IDENTIFY SUCCESS FACTORS: PINPOINT THE MOST IMPORTANT ELEMENTS THAT CONTRIBUTE TO SUCCESSFUL FORECASTING IN EUROPEAN MARKETS.
Webinar Video
